“It's a wonderful morning for Lexicon, our scientists, clinicians and the patients and principal investigators,” summed up CEO and Director Lonnel Coats, as the biotech reported results from a phase 2 ...

Lexicon Pharmaceuticals won't take no for an answer. The Texas pharma—convinced of the value of its diabetes candidate sotagliflozin—has clapped back at its latest rejection from the FDA, asking to be ...

Lexicon Pharmaceuticals spent years jumping and often falling over regulatory hurdles for its new heart drug Inpefa, but, after finally getting an FDA approval this year, it’s now turning to Tom ...

THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its first quarter 2025 financial results on Tuesday, May 13 ...

Every investor in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 48% to be ...

Lexicon Pharmaceuticals (LXRX) has priced its public offering of 32M shares of its common stock, par value $0.001, at $1.30 per share to raise $41.6M. The firm has granted the underwriters a 30-day ...

Lexicon Pharmaceuticals announced that it will present data on diabetic peripheral neuropathic pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025) in ...

Lexicon Pharmaceuticals received FDA approval to market its heart failure drug Inpefa, as well as a broad label compared to rivals like AstraZeneca's Farxiga and Lilly's Jardiance. The company faces ...

THE WOODLANDS, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the successful completion of the End-of-Phase 2 (EOP2) Meeting with the U.S. Food ...